文献速递血栓与止血

非瓣膜性心房颤动合并活动性癌症患者围手术期中断抗凝后的血栓与出血结局

Thrombotic and bleeding outcomes following the perioperative interruption of anticoagulation among patients with nonvalvular atrial fibrillation and active cancer.
PubMed 文献 · J Thromb Haemost · 2022-12-27

单中心回顾性队列研究纳入264例活动性癌症合并心房颤动患者共302次围手术期抗凝中断,30天动脉血栓栓塞风险0.7%(95%CI 0.1%-2.4%),大出血风险1.7%(95%CI 0.6%-3.9%),静脉血栓栓塞0.7%(95%CI 0.1%-2.4%),临床相关非大出血4.3%(95%CI 2.5%-7.3%),全因死亡1.3%(95%CI 0.4%-3.4%),发生1例致死性术后卒中;按常用围手术期管理建议管理时血栓栓塞与出血并发症风险相对较低。

要点

  • 活动性癌症合并房颤患者围手术期中断抗凝后30天动脉血栓栓塞风险0.7%(95%CI 0.1%-2.4%)。
  • 30天大出血风险1.7%(95%CI 0.6%-3.9%),临床相关非大出血4.3%(95%CI 2.5%-7.3%)。
  • 30天全因死亡风险1.3%(95%CI 0.4%-3.4%),发生1例致死性术后卒中。

核心结论

  • 按常用围手术期管理建议管理时,本研究中房颤合并活动性癌症患者围手术期中断抗凝后动脉血栓栓塞和术后出血并发症风险相对较低。

研究设计与样本

  • 单中心回顾性队列研究,纳入2015年8月至2019年5月期间因有创操作需要围手术期中断抗凝的活动性癌症合并心房颤动患者264例,共302次围手术期中断抗凝。

主要发现

  • 30天动脉血栓栓塞风险0.7%(95%CI 0.1%-2.4%),大出血风险1.7%(95%CI 0.6%-3.9%)。
  • 30天静脉血栓栓塞风险0.7%(95%CI 0.1%-2.4%),临床相关非大出血风险4.3%(95%CI 2.5%-7.3%)。
  • 30天全因死亡风险1.3%(95%CI 0.4%-3.4%),发生1例致死性术后卒中。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with cancer are at an increased risk of developing atrial fibrillation (AF) and often need to undergo procedures or surgery that requires periprocedural interruption of anticoagulation. Anticoagulated patients with cancer might be at increased risk of postprocedural thromboembolic and bleeding complications. Data on postprocedural outcomes among patients with concurrent active cancer and AF are sparse. OBJECTIVE: To assess the 30-day risk of postoperative thromboembolic and major bleeding complications after the periprocedural interruption of anticoagulation among patients with AF and active cancer. METHODS: We conducted a single-center retrospective cohort study in patients with active cancer and AF who required periprocedural interruption of anticoagulation for invasive procedures between August 2015 and May 2019. The primary endpoints were the 30-day postoperative risks of arterial thromboembolism (ATE) and major bleeding. The secondary endpoints included the 30-day risks of venous thromboembolism, clinically relevant nonmajor bleeding, and overall mortality. RESULTS: Two hundred sixty-four patients undergoing 302 periprocedural interruptions were included in our study. The 30-day risk of ATE was 0.7% (95% CI, 0.1%-2.4%), and the 30-day risk of major bleeding was 1.7% (95% CI, 0.6%-3.9%). The 30-day risks of venous thromboembolism and clinically relevant nonmajor bleeding were 0.7% (95% CI, 0.1%-2.4%) and 4.3% (95% CI, 2.5%-7.3%), respectively. The overall risk of mortality at 30 days was 1.3% (95% CI, 0.4%-3.4%). There was one fatal postoperative stroke. CONCLUSIONS: Patients with AF and active cancer in this study were at relatively low risk for ATE and postoperative bleeding complications when patients were managed according to commonly applied perioperative management recommendations.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Aziz J, Wang TF, Siegal D, et al. Thrombotic and bleeding outcomes following the perioperative interruption of anticoagulation among patients with nonvalvular atrial fibrillation and active cancer. J Thromb Haemost. 2022. PMID: 36696183. doi:10.1016/j.jtha.2022.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。